Klinische Relevanz und Behandlungsmöglichkeiten von Rapid Cycling bei Patienten mit bipolarer affektiver Störung

B. Amann; R. Stampfer; F. Schmidt; P. Mikhaiel; B. Hummel; A. Sterr; M. Schäfer; H. Grunze

doi:10.1055/s-2001-19181

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2001; 69(12): 569-580
DOI: 10.1055/s-2001-19181

Originalarbeit

Georg Thieme Verlag Stuttgart · New York

Klinische Relevanz und Behandlungsmöglichkeiten von Rapid Cycling bei Patienten mit bipolarer affektiver Störung

Clinical Relevance and Treatment Possibilities of Rapid Cycling in Patients with Bipolar DisorderB. Amann¹ , R. Stampfer¹ , F. Schmidt¹ , P. Mikhaiel¹ , B. Hummel¹ , A. Sterr¹ , M. Schäfer¹ , H. Grunze¹

¹Psychiatrische Universitätsklinik der LMU München (Direktor: Prof. Dr. med. H. J. Möller)

Abstract

Zusammenfassung

Nach den derzeit gültigen diagnostischen Leitlinien des ICD-10 finden Subtypen des bipolaren Spektrums syndromorientiert und in Bezug auf den Verlauf nur randständig Berücksichtigung. Im Gegensatz dazu hat im amerikanischen DSM-IV eine Unterteilung von Bipolar-I-Störung (ausgeprägte manische und depressive Episoden) und Bipolar-II-Störung (hypomanische und depressive Episoden) bereits 1994 Eingang gefunden. Auch wird eine differenzielle Verlaufsbeobachtung der Erkrankung mit klinischer Relevanz, wie das Rapid Cycling (RC), mit einbezogen. Dabei handelt es sich um einen Verlauf einer bipolaren Erkrankung mit mindestens 4 affektiven Episoden in einem Jahr. Für diesen wird ebenso wie bei gemischten Episoden und einem atypischen Beginn (initiale Depression) bei Patienten mit einer bipolaren Erkrankung ein schlechteres Ansprechen auf die Standardtherapie Lithium postuliert. Aufgrund dessen sind medikamentöse Alternativen und zusätzliche Therapieansätze hinsichtlich einer Phasenprophylaxe aus klinischer Sicht dringend notwendig; diese werden im Beitrag auf aktuellem Stand dargestellt und diskutiert. Ebenso werden mit RC assoziierte Parameter wie gehäuftes Auftreten bei Frauen, hypothyreote Stoffwechsellage, bipolarer Subtyp, COMT-Allel, Einfluss durch Schlaf und Induktion durch Antidepressiva dargestellt.

Abstract

In the actual version of the WHO diagnostic guidelines, the ICD-10, subtypes of bipolar disorder are not specified, in contrast to the American DSM-IV, where bipolar disorder has already been differentiated in bipolar I (severe manic and depressive episodes) and bipolar II disorder (depressive and hypomanic episodes). Furthermore, aspects of the longitudinal course of the illness, like rapid cycling (RC), are reflected as well. Rapid cycling is defined as four or more affective episodes within one year of the illness. It has been postulated that rapid cycling is related with a poor response to lithium, to the same extent as mixed episodes or an atypical onset (depressive episode first) of the disease. Here, the current status of alternative pharmacological and supportive therapy of rapid cycling is presented and discussed. Furthermore, the article also displays biological parameters associated with rapid cycling like higher prevalence in women, hypothyreoidism, subtype of bipolar disorder, COMT-allele, influence of sleep or risk of antidepressant induced cycling.

Full Text

References

Literatur

1 Dunner D L, Fieve R R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974; 30 229-233
2 American Psychiatric Association .Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen, Bern, Toronto, Seattle: Hogrefe 1996
3 World Health Organization .The ICD-10 Classification of Mental and behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO 1992
4 Kukopulos A, Caliari B, Tundo A, Minnai G, Floris G, Reginaldi D. et al . Rapid cyclers, temperament, and antidepressants. Compr Psychiatry. 1983; 24 249-258
5 Goodwin F K, Jamison K R. Manic-depressive illness. New York: Oxford University Press 1990
6 Bauer M S, Calabrese J, Dunner D L, Post R, Whybrow P C, Gyulai L. et al . Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry. 1994; 151 506-515
7 Frye M A, Altshuler L L, Szuba M P, Finch N N, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry. 1996; 57 17-21
8 Alarcon R D. Rapid cycling affective disorders: a clinical review. Compr Psychiatry. 1985; 26 522-540
9 Wehr T A, Sack D A, Rosenthal N E, Cowdry R W. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988; 145 179-184
10 Tondo L, Baldessarini R J. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry. 1998; 155 1434-1436
11 Leibenluft E, Ashman S B, Feldman N S, Yonkers K A. Lack of relationship between menstrual cycle phase and mood in a sample of women with rapid cycling bipolar disorder. Biol Psychiatry. 1999; 46 577-580
12 Feldman-Naim S, Turner E H, Leibenluft E. Diurnal variation in the direction of mood switches in patients with rapid-cycling bipolar disorder. J Clin Psychiatry. 1997; 58 79-84
13 Leibenluft E, Albert P S, Rosenthal N E, Wehr T A. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res. 1996; 63 161-168
14 Ashman S B, Monk T H, Kupfer D J, Clark C H, Myers F S, Frank E. et al . Relationship between social rhythms and mood in patients with rapid cycling bipolar disorder. Psychiatry Res. 1999; 86 1-8
15 Bauer M S, Whybrow P C, Winokur A. Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism. Arch Gen Psychiatry. 1990; 47 427-432
16 Cho J T, Bone S, Dunner D L, Colt E, Fieve R R. The effect of lithium treatment on thyroid function in patients with primary affective disorder. Am J Psychiatry. 1979; 136 115-116
17 Cowdry R W, Wehr T A, Zis A P, Goodwin F K. Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry. 1983; 40 414-420
18 Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry. 1992; 49 126-131
19 Bauer M, Hellweg R, Baumgartner A. Hochdosierte Thyroxinbehandlung bei therapie- und prophylaxeresistenten Patienten mit affektiven Psychosen. Nervenarzt. 1998; 69 1019-1022
20 Bauer M S, Whybrow P C. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry. 1990; 47 435-440
21 Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology. 1994; 10 183-189
22 Sack D A, James S P, Rosenthal N E, Wehr T A. Deficient nocturnal surge of TSH secretion during sleep and sleep deprivation in rapid-cycling bipolar illness. Psychiatry Res. 1988; 23 179-191
23 Johnston A M, Eagles J M. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry. 1999; 175 336-339
24 Gutierrez B, Bertranpetit J, Guillamat R, Valles V, Arranz M J, Kerwin R. et al . Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Am J Psychiatry. 1997; 154 113-115
25 Kunugi H, Vallada H P, Hoda F, Kirov G, Gill M, Aitchison K J. et al . No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biol Psychiatry. 1997; 42 282-285
26 Kirov G, Murphy K C, Arranz M J, Jones I, McCandles F, Kunugi H. et al . Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry. 1998; 3 342-345
27 Papolos D F, Veit S, Faedda G L, Saito T, Lachman H M. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Mol Psychiatry. 1998; 3 346-349
28 Geller B, Cook E H. Ultradian rapid cycling in prepubertal and early adolescent bipolarity is not in transmission disequilibrium with val/met COMT alleles. Biol Psychiatry. 2000; 47 605-609
29 Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P. et al . Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. J Clin Psychiatry. 2000; 61 585-593
30 Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980; 13 156-167
31 Tondo L, Laddomada P, Serra G, Minnai G, Kukopulos A. Rapid cyclers and antidepressants. Int Pharmacopsychiatry. 1981; 16 119-123
32 Sachs G S. Treatment-resistant bipolar depression. Psychiatr Clin North Am. 1996; 19 215-236
33 Srisurapanont M, Yatham L N, Zis A P. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry. 1995; 40 533-544
34 Frances A J, Kahn D A, Carpenter D, Docherty J P, Donovan S L. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry. 1998; 59 (Suppl 4) 73-79
35 Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994; 164 549-550
36 Calabrese J R, Rapport D J, Kimmel S E, Shelton M D. Controlled trial in bipolarl I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol. 1999; 9 (Suppl 4) S109-S112
37 Möller H-J, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?. Eur Arch Psychiatry Clin Neurosci. 2000; 250 57-68
38 Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med Spec Report. 2000; 1-104
39 Thase M E, Sachs G S. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000; 48 558-572
40 Kukopulos A, Reginaldi D. Recurrence of manic-depressive episodes during lithium treatment. In: Johnson FN (Hrsg). Handbook of Lithium Therapy. Lancaster: MTP Press 1980
41 Baldessarini R J, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord. 2000; 61 13-22
42 Maj M, Magliano L, Pirozzi R, Marasco C, Guarneri M. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry. 1994; 151 1015-1019
43 Kilzieh N, Akiskal H S. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am. 1999; 22 585-607
44 Swann A C, Secunda S K, Katz M M, Koslow S H, Maas J W, Chang S. et al . Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatry Res. 1986; 18 127-141
45 Secunda S K, Katz M M, Swann A, Koslow S H, Maas J W, Chuang S. et al . Mania. Diagnosis, state measurement and prediction of treatment response. J Affect Disord. 1985; 8 113-121
46 Calabrese J R, Fatemi S H, Kujawa M, Woyshville M J. Predictors of response to mood stabilizers. J Clin Psychopharmacol. 1996; 16 24S-31S
47 Janicak P G, Newman R, Davis J M. Advances in the treatment of mania related disorders: a reappraisal. Psychiatry Ann. 1992; 22 92-103
48 Post R M. Non-lithium treatment for bipolar disorder. J Clin Psychiatry. 1990; 51 Suppl 9-16
49 Stoll A L, Banov M, Kolbrener M, Mayer P V, Tohen M, Strakowski S M. et al . Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994; 14 311-313
50 Grof P, Angst J, Karasek M, Keitner G. Patient selection for long-term lithium treatment in clinical practice. Arch Gen Psychiatry. 1979; 36 894-897
51 Calabrese J R, Woyshville M J, Kimmel S E, Rapport D J. Predictors of valproate response in bipolar rapid cycling. J Clin Psychiatry. 1993; 13 280-283
52 Herridge P L, Pope H G. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol. 1985; 5 229-230
53 McElroy S L, Keck P E, Pope H G, Hudson J I. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol. 1988; 8 275-279
54 Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry. 1989; 50 Suppl 40-43
55 Calabrese J R, Delucchi G A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990; 147 431-434
56 Calabrese J R, Markovitz P J, Kimmel S E, Wagner S C. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol. 1992; 12 53S-56S
57 Grunze H, Amann B, Schäfer M, Sterr A, Schaerer L, Wild E. et al . Wirksamkeit, Verträglichkeit und Praktikabilität von Valproat-Miniretardtabletten bei bipolaren affektiven Störungen. Fortschr Neurol Psychiatr. 2000; 68 496-502
58 Schaff M R, Fawcett J, Zajecka J M. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993; 54 380-384
59 Jacobsen F M. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry. 1993; 54 229-234
60 Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry. 1993; 38 137-139
61 Denicoff K D, Smith-Jackson E E, Bryan A L, Ali S O, Post R M. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry. 1997; 154 1456-1458
62 Schneider A L, Wilcox C S. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord. 1998; 47 201-205
63 Lepkifker E, Iancu I, Dannon P, Ziv R, Kotler M. Valproic acid in ultra-rapid cycling: a case report. Clin Neuropharmacol. 1995; 18 72-75
64 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H. et al . Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology. 1979; 66 211-217
65 Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel R R. et al . Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord. 1997; 43 151-161
66 Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. Br J Psychiatry. 1985; 147 198-200
67 Levy J M, Remick R A. Clinical aspects and treatment of rapid cycling mood disorders. Can J Psychiatry. 1986; 31 436-441
68 Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand. 1991; 83 456-459
69 Joyce P R. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol. 1988; 3 123-129
70 Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology. 1993; 27 138-145
71 Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997; 58 470-478
72 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998; 18 455-460
73 Hesslinger B, Normann C, Langosch J M, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999; 19 310-315
74 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G. et al . A double-blind placebo-controlled study of lamatrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999; 60 79-88
75 Fatemi S H, Rapport D J, Calabrese J R, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 1997; 58 522-527
76 Calabrese J R, Fatemi S H, Woyshville M J. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry. 1996; 153 1236
77 Kusumakar V, Yatham L N. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry. 1997; 154 1171-1172
78 Walden J, Schaerer L O, Schlösser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar disorders. 2000; 2 336-339
79 Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry. 1996; 29 193-195
80 Labbate L A, Rubey R N. Lamotrigine for treatment-refractory bipolar disorder. Am J Psychiatry. 1997; 154 1317
81 Fogelson D L, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry. 1997; 58 271-273
82 Kusumakar V, Yatham L N. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res. 1997; 72 145-148
83 Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol. 1997; 17 185-189
84 Bowden C L, Calabrese J R, McElroy S L, Rhodes L J, Keck P E, Cookson J. et al . The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry. 1999; 45 953-958
85 Calabrese J R, Suppes T, Bowden C L, Sachs G S, Swann A, McElroy S L. et al . A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. J Clin Psychiat. 2000; 61 841-850
86 Stancer H C, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch Gen Psychiatry. 1982; 39 311-312
87 Hurowitz G I, Liebowitz M R. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol. 1993; 13 52-56
88 Leibow D. L-thyroxine for rapid-cycling bipolar illness. Am J Psychiatry. 1983; 140 1255
89 Joffe R T, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990; 32 241-251
90 Gyulai L, Jaggi J, Bauer M S, Younkin S, Rubin L, Attie M. et al . Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder. Biol Psychiatry. 1997; 41 503-506
91 Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. Biol Psychiatry. 1999; 45 229-233
92 Dubovsky S L, Franks R D. Intracellular calcium ions in affective disorders: a review and an hypothesis. Biol Psychiatry. 1983; 18 781-797
93 Walden J, Grunze H, Olbrich H, Berger M. Bedeutung von Kalziumionen und Kalziumantagonisten bei affektiven Psychosen. Fortschr Neurol Psychiatr. 1992; 60 471-476
94 Grunze H, Schlösser S, Amann B, Walden J. Anticonvulsant drugs in bipolar disorder. Dialogues in Clinical Neuroscience. 1999; 1 24-40
95 Manna V. Disturbi affettivi bipolari e ruolo del calcio intraneuronale. Effetti terapeutici del trattamento con sali di litio e/o calcio antagonista in pazienti con rapida inversione di polarita. Minerva Med. 1991; 82 757-763
96 Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1996; 20 419-426
97 Pazzaglia P J, Post R M, Ketter T A, George M S, Marangell L B. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993; 49 257-272
98 Davanzo P A, Krah N, Kleiner J, McCracken J. Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness. J Child Adolesc Psychopharmacol. 1999; 9 51-61
99 Soares J C, Mallinger A G, Gershon S. The role of antipsychiatric agents in the treatment of bipolar disorder patients. Int Clin Psychopharmacol. 1997; 12 65-76
100 Gelenberg A J, Hopkins H S. Antipsychotics in bipolar disorder. J Clin Psychiatry. 1996; 57 Suppl 9 49-52
101 Tohen M, Zarate C A. Antipsychotic agents and bipolar disorder. J Clin Psychiatry. 1998; 59 Suppl 1 38-48
102 Zarate C A, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer?. J Clin Psychiatry. 1995; 56 108-112
103 Zarate C A, Tohen M, Baldessarini R J. Clozapine in severe mood disorders. J Clin Psychiatry. 1995; 56 411-417
104 Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A. et al . Clozapine for treatment-refractory mania. Am J Psychiatry. 1996; 153 759-764
105 Kimmel S E, Calabrese J R, Woyshville M J, Meltzer H Y. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry. 1994; 55 Suppl B 91-93
106 Suppes T, McElroy S L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992; 32 270-280
107 Calabrese J R, Meltzer H Y, Markovitz P J. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol. 1991; 11 396-397
108 Suppes T, Phillips K A, Judd C R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry. 1994; 36 338-340
109 Vieta E, Gasto C, Escobar R. Treatment of dysphoric mania with risperidone. Int J Neuropsychopharmacol. 1995; 10 491-492
110 Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol. 1998; 18 172-174
111 Bauer M S, McBride L, Chase C, Sachs G, Shea N. Manual-based group psychotherapy for bipolar disorder: a feasibility study. J Clin Psychiatry. 1998; 59 449-455
112 Cochran S D. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol. 1984; 52 873-878
113 Frank E, Swartz H A, Mallinger A G, Thase M E, Weaver E V, Kupfer D J. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol. 1999; 108 579-587
114 Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ. 1999; 318 149-153
115 Satterfield J M. Adjunctive cognitive-behavioral therapy for rapid-cycling bipolar disorder: an empirical case study. Psychiatry. 1999; 62 357-369
116 Roy-Byrne P P, Post R M, Uhde T W, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985; 317 1-34
117 Gregory S, Shawcross C R, Gill D. The Nottingham ECT Study. A double-blind comparison of bilateral, unilateral and simulated ECT in depressive illness. Br J Psychiatry. 1985; 146 520-524
118 Black D W, Winokur G, Nasrallah A. Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients. J Clin Psychiatry. 1987; 48 132-139
119 Grunze H, Erfurth A, Schäfer M, Amann B, Meyendorf R. Elektrokonvulsionstherapie in der Behandlung der schweren Manie. Nervenarzt. 1999; 70 662-667
120 Berman E, Wolpert E A. Intractable manic-depressive psychosis with rapid cycling in an 18-year-old woman successfullly treated with electroconvulsive therapy. J Nerv Ment Dis. 1987; 175 236-239
121 Mosolov S N, Moshchevitin S I. Primenenie elektrosudorozhnoi terapii dlia obryva kontinual' - nogo techeniia terapevticheski rezistentnykh affektivnogo i shizoaffektivnogo psikhozov. Zh Nevropatol Psikhiatr Im S S Korsakova. 1990; 90 121-125
122 Devanand D P, Sackeim H A, Decina P, Prudic J. The development of mania and organic euphoria during ECT. J Clin Psychiatry. 1988; 49 69-71
123 Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14 171-180
124 Stoll A L, Sachs G S, Cohen B M, Lafer B, Christensen J D, Renshaw P F. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry. 1996; 40 382-388
125 Bowden C L, Brugger A M, Swann A C, Calabrese J R, Janicak P G, Petty F. et al . Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994; 271 918-924
126 Wehr T A, Goodwin F K. Can antidepressants cause mania and worsen the course of affective illness?. Am J Psychiatry. 1987; 144 1403-1411
127 McElroy S L, Suppes T, Keck P E, Frye M A, Denicoff K D, Altshuler L L. et al . Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000; 47 1025-1033
128 Novac A. Atypical antipsychotics as enhancement therapy in rapid cycling mood states: a case study. Ann Clin Psychiatry. 1998; 10 107-111
129 Pazzaglia P J, Post R M, Ketter T A, Callahan A M, Marangell L B, Frye M A. et al . Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol. 1998; 18 404-413

Dr. B. Amann

Psychiatrie LMU

Nussbaumstr. 7

80336 München

Email: benedikt.amann@psy.med.uni-muenchen.de